HC Wainwright & Co. Initiates Coverage On CARISMA Therapeutics with Buy Rating, Announces Price Target of $10
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and a price target of $10.
May 24, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. initiates coverage on CARISMA Therapeutics with a Buy rating and a price target of $10.
The Buy rating and $10 price target initiated by HC Wainwright & Co. analyst Mitchell Kapoor on CARISMA Therapeutics (NASDAQ:CARM) is a positive signal for the stock. This recommendation suggests that the analyst believes the stock has potential for growth in the short term, which could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100